Answers are grounded in this paper and cite their sources.
Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.).
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: